41602 Achievement of National Psoriasis Foundation (NPF) treatment targets and acceptable responses among patients with psoriasis treated with ixekizumab versus other biologics in head-to- head clinical trials
Armstrong A, Blauvelt A, Papp K, Green L, Feely M, Malatestinic W, See K, McKean-Matthews M, Strober B. 41602 Achievement of National Psoriasis Foundation (NPF) treatment targets and acceptable responses among patients with psoriasis treated with ixekizumab versus other biologics in head-to- head clinical trials. Journal Of The American Academy Of Dermatology 2023, 89: ab12. DOI: 10.1016/j.jaad.2023.07.056.Peer-Reviewed Original Research